These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 31096849

  • 1. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, Landriscina M, Guglielmi G, Storto G.
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [Abstract] [Full Text] [Related]

  • 2. [Targeted radionuclide therapy for castration-resistant prostate cancer].
    Nakamura K, Ohga S, Sasaki T, Baba S, Honda H.
    Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
    [Abstract] [Full Text] [Related]

  • 3. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
    Heinzer H, König F, Klutmann S.
    Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
    [Abstract] [Full Text] [Related]

  • 4. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Nilsson S.
    Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R, Gschwend J, Scheidhauer K, Eiber M, Krönke M.
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [Abstract] [Full Text] [Related]

  • 11. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR, Witten MR, Haas JA.
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [Abstract] [Full Text] [Related]

  • 12. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
    Borsò E, Boni G, Galli L, Ricci S, Farnesi A, Mazzarri S, Cianci C, Mariani G, Falcone A.
    Future Oncol; 2015 Mar; 11(2):323-31. PubMed ID: 25075962
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
    Picciotto M, Franchina T, Russo A, Ricciardi GRR, Provazza G, Sava S, Baldari S, Caffo O, Adamo V.
    Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.